HOME >> MEDICINE >> NEWS
MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology

St. Louis, MO, May 31, 2001--MetaPhore Pharmaceuticals, Inc. today announced that it has received FDA approval of its Investigational New Drug (IND) application to conduct clinical trials in the U.S. to evaluate M40403, one of its enzyme mimetic compounds.

MetaPhore has initiated a Phase I study to test the safety and tolerability and to determine the pharmacokinetics of the compound in normal, healthy human subjects, as a precursor to Phase II trials in which M40403 will be tested as a co-therapy with interleukin-2 (IL-2) for advanced skin and end-stage kidney cancers. This study is the first human clinical trial for MetaPhore and the companys proprietary family of enzyme mimetic compounds that effectively mimic the action of one of the bodys primary free-radical fighting mechanisms, the natural enzyme superoxide dismutase (SOD).

In addition to cancer, MetaPhore is developing these compounds as drug candidates for pain and other diseases and conditions that have been associated with free-radical damage to tissues and cells.

The opening of this IND marks a major step for MetaPhore and our SOD enzyme mimetic program. For many years, we have understood the free-radical fighting power of the bodys natural SOD enzymes, but only recently have we been able to reproduce that benefit in a stable and selective drug form, said Denis Forster, Chief Operating Officer of MetaPhore. These novel therapeutics have tremendous potential, based on the growing body of research linking free-radical mediated damage with a wide range of acute and chronic disease states.

Preclinical studies in animals, including several recently presented at the American Association for Cancer Research at the end of March, have shown that M40403 significantly improves the effectiveness of IL-2, an approved treatment for inoperable metastatic melanoma and metastatic renal-cell carcinoma. Approximately 80,000 cases of melanoma and renal-cell carcinoma are diagnosed in th
'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
30-May-2001


Page: 1 2 3

Related medicine news :

1. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
2. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. Pharmaceuticals and personal care products
6. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. NIAID initiates trial of experimental avian flu vaccine
11. American Academy of Neurology initiates health literacy training for neurologists

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/20/2018)... ... November 20, 2018 , ... The ... Dehgan as the new CEO of Cerebral Palsy Alliance Research Foundation (CPARF). Nadine ... excited to join an organization whose researchers are laser focused on preventing, treating ...
(Date:11/20/2018)... ... November 20, 2018 , ... ... that Larry Whiteside will be leading a companywide focus on data security initiatives ... and methodologies designed to fully protect healthcare practices and patient data. , A ...
(Date:11/20/2018)... ... November 20, 2018 , ... The 2018-19 ski and ... specialist and USSA Ski Team Doctor Dr. Kevin Plancher, “you can’t start your ... a known fact that skiing and snowboarding are high-risk injury sports. According to ...
(Date:11/17/2018)... Ala. (PRWEB) , ... November 17, 2018 , ... First ... In order to show their appreciation, the Eckenrod Ford Lincoln dealership is promoting their ... register for this offer. Below is a full list of careers that are eligible. ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... in the female reproductive system. However, changes in the color, smell, or consistency ... be embarrassing and bothersome and result in a low self-esteem for many women. ...
Breaking Medicine News(10 mins):
(Date:11/16/2018)... ... November 16, 2018 , ... ... of University Veterinary Specialists (UVS), now known as MedVet Pittsburgh. The City Vets ... looks forward to providing local veterinarians continued support and access to specialty and ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... congratulates leading provider organizations for earning prestigious eHealthcare Leadership Awards. These winning ... 17 categories for outstanding healthcare websites and digital communications. , Spanning the ...
(Date:11/16/2018)... ... November 16, 2018 , ... Through its Microbiome ... in study design, planning, sample collection, and analysis to team of researchers at ... maternal depressive symptoms, infant cognitive/behavioral development, and the gut microbiome. , The ...
Breaking Medicine Technology:
Cached News: